MedTrace Logo

Inhaled NO for the Treatment of Viral Pneumonia in Adults

NCT04606407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-12-16

No results posted yet for this study

Summary

The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia

Conditions

  • Viral Pneumonia
  • Nitric Oxide
  • Respiratory Disease
  • Pneumonia, Viral
  • Inhaled Nitric Oxide
  • Covid19
  • SARS-CoV Infection

Interventions

DEVICE

LungFit™

Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)

Sponsors & Collaborators

  • Beyond Air Inc.

    lead INDUSTRY

Principal Investigators

  • Asher Tal · Beyond Air

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2022-08-07
Completion
2022-08-07
FDA Device
Yes

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606407 on ClinicalTrials.gov